12797 related articles for article (PubMed ID: 35864917)
21. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO).
Asgari N
Dan Med J; 2013 Oct; 60(10):B4730. PubMed ID: 24083534
[TBL] [Abstract][Full Text] [Related]
22. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
23. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H; Prohić A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
[TBL] [Abstract][Full Text] [Related]
24. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
[TBL] [Abstract][Full Text] [Related]
25. Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report.
Zhang C; Zhang K; Chen B; Yin J; Dong M; Qin Y; Yang X
BMC Neurol; 2021 Mar; 21(1):109. PubMed ID: 33750325
[TBL] [Abstract][Full Text] [Related]
26. Neuromyelitis Optica Spectrum Disorder.
Cazzaniga J; Jara Silva CE; Quinonez J; Ruxmohan S; Leyva MM; Fahs A
Cureus; 2023 Nov; 15(11):e48168. PubMed ID: 38046734
[TBL] [Abstract][Full Text] [Related]
27. Cases of neuromyelitis optica spectrum disorder from the East Africa region, highlighting challenges in diagnostics and healthcare access.
Sokhi D; Suleiman A; Manji S; Hooker J; Mativo P
eNeurologicalSci; 2021 Mar; 22():100320. PubMed ID: 33553703
[TBL] [Abstract][Full Text] [Related]
28. A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection.
Ghosh R; De K; Roy D; Mandal A; Biswas S; Biswas S; Sengupta S; Naga D; Ghosh M; Benito-León J
J Neuroimmunol; 2020 Nov; 350():577439. PubMed ID: 33333471
[TBL] [Abstract][Full Text] [Related]
29. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
30. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
31. [Optic neuropathy in positive anti-MOG antibody syndrome].
Merabtene L; Vignal Clermont C; Deschamps R
J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
[TBL] [Abstract][Full Text] [Related]
32. A novel association of osmotic demyelination in Sjögren's syndrome prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review.
Sandhya P; Akaishi T; Fujihara K; Aoki M
Mult Scler Relat Disord; 2023 Jan; 69():104466. PubMed ID: 36584554
[TBL] [Abstract][Full Text] [Related]
33. Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity.
Carnero Contentti E; Hryb JP; Morales S; Gomez A; Chiganer E; Di Pace JL; Lessa C; Perassolo M
J Neurol Sci; 2017 Feb; 373():134-137. PubMed ID: 28131170
[TBL] [Abstract][Full Text] [Related]
34. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes.
Lana-Peixoto MA; Talim N
Biomedicines; 2019 Jun; 7(2):. PubMed ID: 31212763
[TBL] [Abstract][Full Text] [Related]
35. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
36. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
37. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
Lin L; Wu Y; Hang H; Lu J; Ding Y
Front Immunol; 2022; 13():853891. PubMed ID: 35898513
[TBL] [Abstract][Full Text] [Related]
38. Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature.
Jayarangaiah A; Sehgal R; Epperla N
BMC Neurol; 2014 Oct; 14():200. PubMed ID: 25291981
[TBL] [Abstract][Full Text] [Related]
39. Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination.
Heekin R; Gandhy C; Robertson D
Case Rep Neurol; 2015; 7(1):78-83. PubMed ID: 25969683
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
